by The global allergy diagnostics and therapeutics market size accounted for US$ 31.64 Bn in 2022 and is projected to reach around USD 61.60 Bn by 2032, growing at a CAGR of 6.89% from 2023 to 2032.
Report Summary
The global allergy diagnostics and therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the allergy diagnostics and therapeutics market across the globe.
A comprehensive estimate on the allergy diagnostics and therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of allergy diagnostics and therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2991
Allergy Diagnostics and Therapeutics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 33.82 Billion |
| Market Size by 2032 | USD 61.60 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.89% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Drug Class, By Test, By Allergen Type, and By End-user |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized allergy diagnostics and therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Digital Breast Tomosynthesis Equipment Market Size Analysis 2023 To 2032
Allergy Diagnostics and Therapeutics Market Players
The report includes the profiles of key allergy diagnostics and therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- R-Biopharm AG
- EUROIMMUN Medizinische Labordiagnostika AG
- DASIT Group SPA
- bioMérieux
- Thermo Fisher Scientific, Inc.
- Stallergenes Greer
- Sun Pharmaceutical Industries Ltd
- Minaris Medical America, Inc.
- Siemens Healthcare GmbH
- AESKU.GROUP GmbH
- Omega Diagnostics Group PLC
- HYCOR Biomedical
- Lincoln Diagnostics, Inc.
- Alcon
- Astellas Pharma Inc.
- HOB Biotech Group Corp., Ltd.
- Danaher
- AbbVie, Inc.
- Allergy Therapeutics
- Sanofi
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
Market Segmentation
By Product
- Instruments
- Consumables
- Services
By Drug Class
- Nasal Anti-cholinergic
- Antihistamines
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Epinephrine
- Immunotherapy
- Decongestants
- Immuno-modulators
By Test
- In vivo Test
- In vitro Test
By Allergen Type
- Food
- Inhaled
- Drug
- Other Allergens
By End-user
- Hospitals
- Diagnostics Labs
- Research & Development Centers
- Others
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Allergy Diagnostics and Therapeutics Market
5.1. COVID-19 Landscape: Allergy Diagnostics and Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Allergy Diagnostics and Therapeutics Market, By Product
8.1. Allergy Diagnostics and Therapeutics Market, by Product, 2023-2032
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Allergy Diagnostics and Therapeutics Market, By Drug Class
9.1. Allergy Diagnostics and Therapeutics Market, by Drug Class, 2023-2032
9.1.1. Nasal Anti-cholinergic
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Antihistamines
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Corticosteroids
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Mast Cell Stabilizers
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Leukotriene Inhibitors
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Epinephrine
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Immunotherapy
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Decongestants
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Immuno-modulators
9.1.9.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Allergy Diagnostics and Therapeutics Market, By Test
10.1. Allergy Diagnostics and Therapeutics Market, by March, 2023-2032
10.1.1. In vivo Test
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. In vitro Test
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Allergy Diagnostics and Therapeutics Market, By By Allergen Type
11.1. Allergy Diagnostics and Therapeutics Market, by By Allergen Type, 2023-2032
11.1.1. Food
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Inhaled
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Drug
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Other Allergens
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Allergy Diagnostics and Therapeutics Market, By End-user
12.1. Allergy Diagnostics and Therapeutics Market, by End-user, 2023-2032
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Diagnostics Labs
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Research & Development Centers
12.1.3.1. Market Revenue and Forecast (2020-2032)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Allergy Diagnostics and Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.3. Market Revenue and Forecast, by Test(2020-2032)
13.1.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.1.5. Market Revenue and Forecast, by End-user (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.1.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.1.6.5. Market Revenue and Forecast, by End-user (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Test(2020-2032)
13.1.7.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.1.7.5. Market Revenue and Forecast, by End-user (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.5. Market Revenue and Forecast, by End-user (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.7. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.8. Market Revenue and Forecast, by End-user (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.10. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.11. Market Revenue and Forecast, by End-user (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.12.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.13. Market Revenue and Forecast, by End-user (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.14.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.15. Market Revenue and Forecast, by End-user (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.5. Market Revenue and Forecast, by End-user (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.7. Market Revenue and Forecast, by End-user (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.9. Market Revenue and Forecast, by End-user (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.10.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.10.5. Market Revenue and Forecast, by End-user (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.11.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.11.5. Market Revenue and Forecast, by End-user (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.5. Market Revenue and Forecast, by End-user (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.7. Market Revenue and Forecast, by End-user (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.9. Market Revenue and Forecast, by End-user (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.10.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.10.5. Market Revenue and Forecast, by End-user (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.11.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.11.5. Market Revenue and Forecast, by End-user (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.3. Market Revenue and Forecast, by Test(2020-2032)
13.5.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.5.5. Market Revenue and Forecast, by End-user (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.5.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.5.7. Market Revenue and Forecast, by End-user (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Test(2020-2032)
13.5.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.5.8.5. Market Revenue and Forecast, by End-user (2020-2032)
Chapter 14. Company Profiles
14.1. R-Biopharm AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. EUROIMMUN Medizinische Labordiagnostika AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. DASIT Group SPA
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. bioMérieux
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Stallergenes Greer
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sun Pharmaceutical Industries Ltd
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Minaris Medical America, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Siemens Healthcare GmbH
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AESKU.GROUP GmbH
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
